Abstract |
We evaluated several 3-day antimicrobial regimens in the treatment of experimental endocarditis caused by an oxacillin-resistant Staphylococcus aureus strain exhibiting intermediate susceptibility in vitro to vancomycin (VISA). Neither vancomycin alone nor trovafloxacin exhibited in vivo efficacy; addition of amikacin to vancomycin yielded a modest in vivo effect. In contrast, the combination of ampicillin and sulbactam was highly effective in vivo, causing a mean decrease in VISA vegetation densities of >5 log(10) CFU/g versus those of untreated controls.
|
Authors | M Backo, E Gaenger, A Burkart, Y L Chai, A S Bayer |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 43
Issue 10
Pg. 2565-8
(Oct 1999)
ISSN: 0066-4804 [Print] United States |
PMID | 10508047
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- sultamicillin
- Vancomycin
- Ampicillin
- Sulbactam
|
Topics |
- Ampicillin
(therapeutic use)
- Animals
- Anti-Bacterial Agents
(pharmacology)
- Disease Models, Animal
- Drug Resistance, Microbial
- Drug Therapy, Combination
(therapeutic use)
- Endocarditis, Bacterial
(drug therapy, microbiology)
- Microbial Sensitivity Tests
- Rabbits
- Staphylococcal Infections
(drug therapy)
- Staphylococcus aureus
(drug effects)
- Sulbactam
(therapeutic use)
- Vancomycin
(pharmacology)
|